Show simple item record

dc.contributor.authorSweeney, S
dc.contributor.authorGomez, G
dc.contributor.authorKitson, N
dc.contributor.authorSinha, A
dc.contributor.authorYatskevich, N
dc.contributor.authorStaples, S
dc.contributor.authorMoodliar, R
dc.contributor.authorMotlhako, S
dc.contributor.authorMaloma, M
dc.contributor.authorRassool, M
dc.contributor.authorNgubane, N
dc.contributor.authorNdlovu, E
dc.contributor.authorNyang'wa, B-T
dc.date.accessioned2020-11-19T17:09:52Z
dc.date.available2020-11-19T17:09:52Z
dc.date.issued2020-10-10
dc.date.submitted2020-11-04
dc.identifier.pmid33039989
dc.identifier.doi10.1136/bmjopen-2019-036599
dc.identifier.urihttp://hdl.handle.net/10144/619756
dc.description.abstractIntroduction: Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are much greater than those for treating drug-susceptible TB, both for health service and patient-incurred costs. Urgent action is needed to identify short, effective, tolerable and cheaper treatments for people with both quinolone-susceptible and quinolone-resistant MDR-TB. We present the protocol for an economic evaluation (PRACTECAL-EE substudy) alongside an ongoing clinical trial (TB-PRACTECAL) aiming to assess the costs to patients and providers of new regimens, as well as their cost-effectiveness and impact on participant poverty levels. This substudy is based on data from the three countries participating in the main trial. Methods and analysis: Primary cost data will be collected from the provider and patient perspectives, following economic best practice. We will estimate the probability that new MDR-TB regimens containing bedaquiline, pretomanid and linezolid are cost-effective from a societal perspective as compared with the standard of care for MDR-TB patients in Uzbekistan, South Africa and Belarus. Analysis uses a Markov model populated with primary cost and outcome data collected at each study site. We will also estimate the impact of new regimens on prevalence of catastrophic patient costs due to TB. Ethics and dissemination: Ethical approval has been obtained from the London School of Hygiene & Tropical Medicine and Médecins Sans Frontières. Local ethical approval will be sought in each study site. The results of the economic evaluation will be shared with the country health authorities and published in a peer-reviewed journal.en_US
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.rightsWith thanks to BMJ Publishing Group.en_US
dc.subjectclinical trials
dc.subjecthealth economics
dc.subjecttuberculosis
dc.titleCost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy.en_US
dc.typeArticle
dc.identifier.eissn2044-6055
dc.identifier.journalBMJ openen_US
dc.source.journaltitleBMJ open
dc.source.volume10
dc.source.issue10
dc.source.beginpagee036599
dc.source.endpage
refterms.dateFOA2020-11-19T17:09:53Z
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Sweeney et al 2020 Cost-effect ...
Size:
640.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record